Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis

  • Claudia Fabiani
  • Antonio Vitale
  • Giacomo Emmi
  • Alice Bitossi
  • Giuseppe Lopalco
  • Jurgen Sota
  • Silvana Guerriero
  • Ida Orlando
  • Marco Capozzoli
  • Fiorella Fusco
  • Francesco Rana
  • Florenzo Iannone
  • Bruno Frediani
  • Mauro Galeazzi
  • Lorenzo Vannozzi
  • Gian Marco Tosi
  • Luca Cantarini
Original Article

Abstract

The aim of the present study was to compare long-term adalimumab (ADA) and infliximab (IFX) retention rates in patients with intermediate, posterior, or panuveitis. Additional aims are as follows: (i) to identify any difference in the causes of treatment discontinuation between patients treated with ADA and IFX; (ii) to assess any impact of demographic features, concomitant treatments, and different lines of biologic therapy on ADA and IFX retention rates; and (iii) to identify any correlation between ADA and IFX treatment duration and the age at uveitis onset, the age at onset of the associated systemic diseases, and the age at the start of treatment. Clinical, therapeutic, and demographic data from patients with non-infectious intermediate, posterior, or panuveitis treated with ADA or IFX were retrospectively collected. Kaplan-Meier plot and log-rank (Mantel-Cox) test were used to assess survival curves. One hundred eight patients (188 eyes) were enrolled; in 87 (80.6%) patients, uveitis was associated with a systemic disease. ADA and IFX were administered in 62 and 46 patients, respectively. No statistically significant differences were identified between ADA and IFX retention rates (p value = 0.22). Similarly, no differences were identified between ADA and IFX retention rates in relation to gender (p value = 0.61 for males, p value = 0.09 for females), monotherapy (p value = 0.08), combination therapy with conventional disease-modifying antirheumatic drugs (log-rank p value = 0.63), and different lines of biologic therapy (p value = 0.79 for biologic-naïve patients; p value = 0.81 for subjects previously treated with other biologics). In conclusion, ADA and IFX have similar long-term retention rates in patients with non-infectious intermediate, posterior, and panuveitis. Demographic, clinical, and therapeutic features do not affect their long-term effectiveness.

Keywords

Adalimumab Biologic therapy Drug retention rate Infliximab Uveitis 

Notes

Compliance with ethical standards

The study protocol was conformed to the tenets of the Declaration of Helsinki, and the Ethics Committee of Azienda Ospedaliera Universitaria Senese, Siena, Italy, approved the study. Informed consent was obtained from all patients enrolled.

Disclosures

None.

References

  1. 1.
    Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140:509–516CrossRefPubMedGoogle Scholar
  2. 2.
    Fabiani C, Vitale A, Orlando I, Capozzoli M, Fusco F, Rana F, Franceschini R, Sota J, Frediani B, Galeazzi M, Marco Tosi G, Cantarini L (2017) Impact of uveitis on quality of life: a prospective study from a tertiary referral rheumatology-ophthalmology collaborative uveitis center in Italy. Isr Med Assoc J 19:478–483PubMedGoogle Scholar
  3. 3.
    Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A (1996) Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 80:332–336CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Gritz DC, Wong IG (2004) Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 111:491–500CrossRefPubMedGoogle Scholar
  5. 5.
    Jaffe GJ, Dick AD, Brézin AP, Nguyen QD, Thorne JE, Kestelyn P, Barisani-Asenbauer T, Franco P, Heiligenhaus A, Scales D, Chu DS, Camez A, Kwatra NV, Song AP, Kron M, Tari S, Suhler EB (2016) Adalimumab in patients with active noninfectious uveitis. N Engl J Med 375:932–943CrossRefPubMedGoogle Scholar
  6. 6.
    Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, Schlaen A, Pavesio C, Cimino L, Van Calster J, Camez AA, Kwatra NV, Song AP, Kron M, Tari S, Brézin AP (2016) Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 388:1183–1192CrossRefPubMedGoogle Scholar
  7. 7.
    Suhler EB, Jaffe GJ, Nguyen QD, Antoine P. Brezin, Manfred Zierhut, Albert Vitale, van Velthoven M, Adan A, Lim L, Kramer M, Schlaen A, Fortin E, Muccioli C, Goto H, Kaburaki T, Camez A, Song AP, Kron M, Tari S, Dick AD (2016) Long-term safety and efficacy of adalimumab in patients with non-infectious intermediate, posterior, or panuveitis in an ongoing open-label study [abstract 1335]. Arthritis Rheumatol 68(Suppl 10)Google Scholar
  8. 8.
    Ramanan AV, Dick AD, Benton D, Compeyrot-Lacassagne S, Dawoud D, Hardwick B, Hickey H, Hughes D, Jones A, Woo P, Edelsten C, Beresford MW (2014) A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). Trials 15:14CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Fabiani C, Vitale A, Emmi G, Vannozzi L, Lopalco G, Guerriero S, Orlando I, Franceschini R, Bacherini D, Cimino L, Soriano A, Frediani B, Galeazzi M, Iannone F, Tosi GM, Salvarani C, Cantarini L (2017) Efficacy and safety of adalimumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol 36:183–189CrossRefPubMedGoogle Scholar
  10. 10.
    Rudwaleit M, Rødevand E, Holck P, Vanhoof J, Kron M, Kary S, Kupper H (2009) Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 68:696–701CrossRefPubMedGoogle Scholar
  11. 11.
    Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M (2012) Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol 250:713–720CrossRefPubMedGoogle Scholar
  12. 12.
    Fabiani C, Vitale A, Lopalco G, Iannone F, Frediani B, Cantarini L (2016) Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art. Clin Rheumatol 35:2631–2638CrossRefPubMedGoogle Scholar
  13. 13.
    Quartier P, Baptiste A, Despert V, Allain-Launay E, Koné-Paut I, Belot A, Kodjikian L, Monnet D, Weber M, Elie C, Bodaghi B, ADJUVITE Study Group (2017) ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Ann Rheum Dis.  https://doi.org/10.1136/annrheumdis-2017-212089
  14. 14.
    Cordero-Coma M, Sobrin L (2015) Anti-tumor necrosis factor-α therapy in uveitis. Surv Ophthalmol 60:575–589CrossRefPubMedGoogle Scholar
  15. 15.
    Markomichelakis N, Delicha E, Masselos S, Fragiadaki K, Kaklamanis P, Sfikakis PP (2011) A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet’s disease: a comparative 4-week study. Rheumatology (Oxford) 50:593–597CrossRefGoogle Scholar
  16. 16.
    Guzelant G, Ucar D, Esatoglu SN, Hatemi G, Ozyazgan Y, Yurdakul S, Seyahi E, Yazici H, Hamuryudan V (2017) Infliximab for uveitis of Behçet’s syndrome: a trend for earlier initiation. Clin Exp Rheumatol 35(Suppl 108):86–89PubMedGoogle Scholar
  17. 17.
    Keino H, Okada AA, Watanabe T, Nakayama M, Nakamura T (2017) Efficacy of infliximab for early remission induction in refractory uveoretinitis associated with Behçet disease: a 2-year follow-up study. Ocul Immunol Inflamm 25:46–51CrossRefPubMedGoogle Scholar
  18. 18.
    Fabiani C, Sota J, Vitale A, Emmi G, Vannozzi L, Bacherini D, Lopalco G, Guerriero S, Venerito V, Orlando I, Franceschini R, Fusco F, Frediani B, Galeazzi M, Iannone F, Tosi GM, Cantarini L (2017) Ten-year retention rate of infliximab in patients with Behçet’s disease-related uveitis. Ocul Immunol Inflamm:1–6.  https://doi.org/10.1080/09273948.2017.1391297
  19. 19.
    Fabiani C, Sota J, Vitale A, Rigante D, Emmi G, Vannozzi L, Bacherini D, Lopalco G, Guerriero S, Gentileschi S, Capozzoli M, Franceschini R, Frediani B, Galeazzi M, Iannone F, Tosi GM, Cantarini L (2017) Cumulative retention rate of adalimumab in patients with Behçet’s disease-related uveitis: a four-year follow-up study. Br J Ophthalmol.  https://doi.org/10.1136/bjophthalmol-2017-310733
  20. 20.
    Cantarini L, Talarico R, Generali E, Emmi G, Lopalco G, Costa L, Silvestri E, Caso F, Franceschini R, Cimaz R, Iannone F, Galeazzi M, Selmi C (2017) Safety profile of biologic agents for Behçet’s disease in a multicenter observational cohort study. Int J Rheum Dis 20:103–108CrossRefPubMedGoogle Scholar
  21. 21.
    Abásolo L, Rosales Z, Díaz-Valle D, Gómez-Gómez A, Peña-Blanco RC, Prieto-García Á, Benítez-Del-Castillo JM, Pato E, García-Feijoo J, Fernández-Gutiérrez B, Rodriguez-Rodriguez L (2016) Immunosuppressive drug discontinuation in noninfectious uveitis from real-life clinical practice: a survival analysis. Am J Ophthalmol 169:1–8CrossRefPubMedGoogle Scholar
  22. 22.
    Sakamoto M, Akazawa K, Nishioka Y, Sanui H, Inomata H, Nose Y (1995) Prognostic factors of vision in patients with Behçet disease. Ophthalmology 102:317–321CrossRefPubMedGoogle Scholar
  23. 23.
    Kang EH, Park JW, Park C, Yu HG, Lee EB, Park MH, Song YW, Song YW (2013) Genetic and non-genetic factors affecting the visual outcome of ocular Behcet’s disease. Hum Immunol 74:1363–1367CrossRefPubMedGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2018

Authors and Affiliations

  • Claudia Fabiani
    • 1
    • 2
  • Antonio Vitale
    • 3
  • Giacomo Emmi
    • 4
  • Alice Bitossi
    • 5
  • Giuseppe Lopalco
    • 6
  • Jurgen Sota
    • 3
  • Silvana Guerriero
    • 7
  • Ida Orlando
    • 3
  • Marco Capozzoli
    • 2
  • Fiorella Fusco
    • 2
  • Francesco Rana
    • 2
  • Florenzo Iannone
    • 6
  • Bruno Frediani
    • 3
  • Mauro Galeazzi
    • 3
  • Lorenzo Vannozzi
    • 5
  • Gian Marco Tosi
    • 2
  • Luca Cantarini
    • 3
  1. 1.Department of OphthalmologyHumanitas Clinical and Research CenterRozzanoItaly
  2. 2.Ophthalmology Unit, Department of Medicine, Surgery and NeuroscienceUniversity of SienaSienaItaly
  3. 3.Research Center of Systemic Autoinflammatory Diseases, Behçet’s Disease Clinic and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and NeurosciencesUniversity of SienaSienaItaly
  4. 4.Department of Experimental and Clinical MedicineUniversity of FlorenceFlorenceItaly
  5. 5.Department of Surgery and Translational Medicine, Eye ClinicUniversity of FlorenceFlorenceItaly
  6. 6.Interdisciplinary Department of Medicine, Rheumatology UnitUniversity of BariBariItaly
  7. 7.Department of Ophthalmology and OtolaryngologyUniversity of BariBariItaly

Personalised recommendations